Pancreatic Cancer Research

ResearcherAccuronix Therapeutics, Inc.Active in the last 2 years

William G. Hawkins

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7087-3585; OpenAlex author ID A5060050760, A5108476490; NIH RePORTER profile ID 6331590. Sources: funder_awards.

Their work

Papers
56 (first author 2, last author 11)
Trials
2 (principal investigator on 2)
Grants
8
Labs led
2
Collaborators
191
Papers, trials and grants by year

2005: 1 grant · 2006: none · 2007: 1 trial · 2008: none · 2009: none · 2010: none · 2011: 3 papers, 1 grant · 2012: 5 papers · 2013: 3 papers · 2014: 3 papers · 2015: 1 paper, 1 trial · 2016: 3 papers, 1 grant · 2017: 5 papers · 2018: 4 papers · 2019: 3 papers · 2020: 3 papers, 1 grant · 2021: 3 papers, 1 grant · 2022: 4 papers, 1 grant · 2023: 8 papers · 2024: 6 papers · 2025: 1 paper · 2026: 1 paper, 2 grants

Papers 50 of 56

  1. Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer. Co-author DOI 10.1126/sciadv.aei1190↗
  2. Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer. Co-author DOI 10.1126/sciimmunol.adp3978↗
  3. Female-specific pancreatic cancer survival from CT imaging of visceral fat implicates glutathione metabolism in solid tumors. Co-author DOI 10.1016/j.acra.2023.11.012↗
  4. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Co-author DOI 10.1038/s41467-024-46811-w↗
  5. Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2024.2320411↗
  6. Neoadjuvant Chemotherapy is Associated with Increased Risk of Postoperative DVT After Distal Pancreatectomy for Pancreatic Adenocarcinoma: a NSQIP Analysis. Last author DOI 10.1245/s10434-023-14763-y↗
  7. ASO Author Reflections: A Role for Extended VTE Prophylaxis After Neoadjuvant Therapy and Distal Pancreatectomy for Pancreatic Adenocarcinoma. First author DOI 10.1245/s10434-023-14849-7↗
  8. Plasma Ceramide C24:0/C16:0 Ratio is Associated with Improved Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-16245-1↗
  9. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology. Last author DOI 10.1007/s00262-023-03463-x↗
  10. Area deprivation and rurality impact overall survival and adjuvant therapy administration in patients with pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1016/j.hpb.2023.08.005↗
  11. MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial. Co-author DOI 10.1016/j.ijrobp.2022.07.015↗
  12. High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival. Co-author DOI 10.1038/s41698-023-00455-z↗
  13. Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy. Co-author DOI 10.1084/jem.20212062↗
  14. Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansio… Co-author DOI 10.1158/1078-0432.ccr-23-2993↗
  15. Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-21-0946↗
  16. Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for pa… Co-author DOI 10.1186/s40170-023-00306-2↗
  17. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Co-author DOI 10.1038/s41588-022-01157-1↗
  18. Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. Co-author DOI 10.1158/1078-0432.ccr-22-0308↗
  19. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer. Co-author DOI 10.3389/fimmu.2022.1039226↗
  20. Oncogenic Kras-Mediated Cytokine CCL15 Regulates Pancreatic Cancer Cell Migration and Invasion through ROS. Co-author DOI 10.3390/cancers14092153↗
  21. Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Co-author DOI 10.1016/j.adro.2020.06.010↗
  22. Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-21-0998↗
  23. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  24. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.02.008↗
  25. Tumor-insular Complex in Neoadjuvant Treated Pancreatic Ductal Adenocarcinoma Is Associated With Higher Residual Tumor. Co-author DOI 10.1097/pas.0000000000001454↗
  26. B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-19-0349↗
  27. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pa… Co-author DOI 10.1097/sla.0000000000003468↗
  28. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Co-author DOI 10.1126/scitranslmed.aau9240↗
  29. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  30. Utility of Endoscopic Ultrasound in Evaluating Local Recurrence After Surgery for Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2018.02.031↗
  31. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Co-author DOI 10.1038/s41467-018-03600-6↗
  32. Residual Tumor Index: A Prognostically Significant Pathologic Parameter in Neoadjuvant-treated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/pas.0000000000001144↗
  33. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic du… Co-author DOI 10.1136/gutjnl-2017-313738↗
  34. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up. Last author DOI 10.1016/j.hpb.2017.01.012↗
  35. Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Co-author DOI 10.1016/j.immuni.2017.07.014↗
  36. Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochond… Last author DOI 10.1186/s12885-016-3040-4↗
  37. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. Last author DOI 10.1186/s13046-016-0470-4↗
  38. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  39. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/s1470-2045(16)00078-4↗
  40. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pa… Co-author DOI 10.1097/coc.0000000000000003↗
  41. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Last author DOI 10.18632/oncotarget.9551↗
  42. Natural history of preoperative subcentimeter pulmonary nodules in patients with resectable pancreatic adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1097/sla.0000000000000719↗
  43. Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. Last author DOI 10.1016/j.molonc.2014.03.005↗
  44. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
  45. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Co-author DOI 10.6004/jnccn.2014.0106↗
  46. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Last author DOI 10.1007/s10637-012-9866-y↗
  47. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. Co-author DOI 10.1371/journal.pone.0077243↗
  48. A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4236/jct.2013.43096↗
  49. Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Co-author DOI 10.1001/archsurg.2012.1126↗
  50. Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. Last author DOI 10.1016/j.surg.2012.05.014↗

Trials 2

  1. Whipple Procedure: Standard of Care vs. Thunderbeat Principal investigator NCT02204124↗
  2. Reinforced Staple Line on Leak Rate in Distal Pancreatectomy Principal investigator NCT01359410↗

Grants 8

  1. Core A: Administrative Core P50CA272213↗
  2. Preclinical Development of the Novel Inhibitor of Apoptosis Proteins S2/IAPinh for Cancer Therapy R01CA276378↗
  3. Preclinical Development of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC) R42CA239853↗
  4. On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49 R01CA163764↗
  5. Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy P50CA196510↗
  6. Translational Research Grant: William Hawkins AWARD pancan:2016-william-hawkins-translational-research-grant-william-haw
  7. ON THE TRAIL TO PANCREAS CANCER-SELECTIVE TUMOR CELL DEATH (APOPTOSIS) R21CA150945↗
  8. Assessing the Ability of Regulatory T-Cell Depletion to Augment Xenogeneic DNA Vaccination Against Mesothelin as a Method to Overcome Immunologic Tolerance in … AWARD pancan:2005-william-g-hawkins-md-assessing-the-ability-of-regulatory-t-ce

Closest collaborators

The 25 strongest of 191 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ryan C Fields · 25 shared papers, 2 shared grants, 2013–2026 · strength 3.74
  2. David G DeNardo · 23 shared papers, 2 shared grants, 2013–2026 · strength 3.52
  3. Dirk M. Spitzer · 6 shared papers, 2 shared grants, 2012–2026 · strength 2.13
  4. Kian‐Huat Lim · 10 shared papers, 1 shared grant, 2016–2026 · strength 2.09
  5. William E. Gillanders · 6 shared papers, 2 shared grants, 2011–2026 · strength 1.71
  6. Andrea Wang‐Gillam · 15 shared papers, 1 shared grant, 2011–2026 · strength 1.46
  7. Graham D. Hogg · 8 shared papers, 2019–2025 · strength 1.10
  8. Roheena Z. Panni · 8 shared papers, 2013–2026 · strength 0.76
  9. C. Alston James · 5 shared papers, 2021–2024 · strength 0.74
  10. Keenan J. Robbins · 2 shared papers, 2024 · strength 0.71
  11. Bradley T. Keller · 1 shared grant, 2022 · strength 0.66
  12. Feng Gao · 6 shared papers, 2011–2026 · strength 0.64
  13. Chong Zuo · 6 shared papers, 2017–2023 · strength 0.62
  14. Albert Craig Lockhart · 5 shared papers, 1 shared grant, 2013–2023 · strength 0.60
  15. John M. Baer · 5 shared papers, 2018–2023 · strength 0.59
  16. Varintra E. Lander · 4 shared papers, 2020–2025 · strength 0.56
  17. Dominic E. Sanford · 5 shared papers, 2013–2026 · strength 0.54
  18. Benjamin R. Tan · 6 shared papers, 2013–2023 · strength 0.53
  19. Linda R. Peterson · 3 shared papers, 2023–2024 · strength 0.52
  20. Joseph E. Ippolito · 3 shared papers, 2023–2024 · strength 0.52
  21. David C. Linehan · 11 shared papers, 2011–2018 · strength 0.50
  22. Usman Younis Panni · 3 shared papers, 2023–2024 · strength 0.48
  23. Liang‐I Kang · 3 shared papers, 2020–2025 · strength 0.46
  24. Timothy M. Nywening · 5 shared papers, 2016–2024 · strength 0.42
  25. Vikram S. Pothuri · 2 shared papers, 2023–2024 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.